Using intravenous topiramate to treat severe seizures that don't respond to other medications.
Official title: Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.
Funded at Prevep, INC. · NIH-10932890 · Data updated 2026-11-12
This study is looking at how well intravenous topiramate can help people with severe seizures that don’t respond to regular treatments, hoping to offer a better option for those in need.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Prevep, INC. NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $367,387 |
| NIH project number | 5R43NS132659-02 |
| Project ID | NIH-10932890 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals experiencing status epilepticus or refractory status epilepticus who have not responded to first- and second-line anti-seizure medications.
✕Less likely to help
Patients who do not have status epilepticus or refractory status epilepticus may not benefit from this research.
What this research studies
This research focuses on treating status epilepticus (SE) and refractory status epilepticus (RSE), which are serious neurological emergencies that often do not respond to standard anti-seizure medications. The study aims to evaluate the effectiveness of intravenous topiramate, a medication that has shown promise in previous cases of treatment-resistant seizures. By administering topiramate intravenously, the researchers hope to provide a more effective option for patients experiencing severe seizures. The approach is based on the medication's unique mechanism of action and its potential neuroprotective benefits.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from severe and treatment-resistant seizures.
How similar studies have gone: Previous research has indicated that intravenous topiramate may be effective in treating highly resistant seizures, suggesting potential success for this approach.
Where this research is happening
-
Prevep, INC.
Bethesda, United States Active
Researchers
- Principal investigator: Klein, Pavel — Prevep, INC.
- Study coordinator: Klein, Pavel
Related research
Other NIH-funded projects on the same topics.
-
Microglia Help Finish Seizures and Heal the Brain
Scientists are studying how brain immune cells (microglia) help end severe seizures and repair brain damage, with potential new ideas for people who have had status epilepticus.
-
ARISEN Network pilot funding to advance autoimmune encephalitis and NORSE care
A pilot grants program within the ARISEN network offers small funding to researchers to speed up clinical trials and improve management and treatment of autoimmune encephalitis, Rasmussen syndrome, and NORSE.
-
ARISEN Network: Better Diagnosis and Treatment for Autoimmune Brain Inflammation in Children
A large team at Emory is building ways to diagnose autoimmune brain inflammation in kids earlier and tailor treatments to improve outcomes.
-
ARISEN Network: Patient-centered outcomes in autoimmune brain inflammation and status epilepticus
A nationwide registry study from Emory will collect patient- and caregiver-reported outcomes to understand how neuroinflammatory brain diseases affect people and what helps them most.
-
ARISEN: A regional network to understand autoimmune brain diseases in kids
A national, multi-center effort follows children with autoimmune brain diseases to better understand how their condition progresses and how it affects thinking and everyday life.
-
ARISEN: Advancing research on autoimmune brain diseases and neuroinflammation
This grant supports a Career Enhancement Core to train the next generation of clinician-scientists studying autoimmune brain diseases like autoimmune encephalitis, Rasmussen’s syndrome, and NORSE, with a focus on pediatric cases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.